Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling
This article was originally published in The Tan Sheet
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.
You may also be interested in...
Clovis, CEO Patrick Mahaffy and former CFO Erie Mast will pay more than $20m to settle charges by the SEC that the company misled investors on the efficacy of rociletinib. Clovis raised $298m in a public stock offering during the timeframe SEC says it misled investors.
Procter & Gamble petitions the Supreme Court to overturn a decision giving class action certification to a complaint alleging the firm deceived consumers with its “snake oil” Align probiotic. If the court overturns the lower court, the action could make class action certifications more difficult.
Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.